Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00245271
Recruitment Status : Completed
First Posted : October 27, 2005
Last Update Posted : June 27, 2011
Information provided by:
Omeros Corporation

Brief Summary:
OMS103HP is being developed for improvement in knee function following ACL reconstruction. Secondary benefits being evaluated include reduced postoperative pain, improvement in knee motion and earlier return to work.

Condition or disease Intervention/treatment Phase
Anterior Cruciate Ligament Reconstruction Drug: OMS103HP Drug: Vehicle Phase 3

Detailed Description:
The anterior cruciate ligament (ACL) is an important stabilizer of the knee. Orthopedic surgeons replace the torn ligament during ACL reconstruction surgery. Surgical trauma initiates an acute inflammatory response, including swelling and pain, that leads to restricted joint motion and loss of function. Because of the dynamic nature, complexity and redundancy of the chemical mediators of inflammation and pain and their pathways, no currently available single drug has sufficiently broad spectrum of activity to effectively inhibit the inflammatory process. OMS103 provides a multicomponent approach to controlling the inflammation induced by arthroscopic surgery. It delivers three active ingredients, each with distinct pharmacological activities, directly to the site of surgical procedures to preemptively block the inflammatory cascade induced by surgical trauma.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 480 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-Blind, Multicenter Study Evaluating the Safety of OMS103HP and Vehicle in Subjects Undergoing Anterior Cruciate Ligament Reconstruction With an Open-Label Phase Containing a PK Analysis in a Subset of Subjects
Study Start Date : October 2004
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
OMS103 Irrigation Solution
Drug: OMS103HP
Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours
Placebo Comparator: 2
Balanced Salt Solution (BSS)
Drug: Vehicle
Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.

Primary Outcome Measures :
  1. The overall incidence of adverse events regardless of relationship to study drug. [ Time Frame: 90 days ]

Secondary Outcome Measures :
  1. Measures of safety and tolerability (e.g., clinical laboratory tests, physical examinations, etc.). [ Time Frame: 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   17 Years to 65 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 17 - 65 years of age
  • In good general health
  • Undergoing arthroscopic ACL reconstruction for an ACL tear

Exclusion Criteria:

  • Allergies to any of the individual ingredients in OMS103HP
  • Has open physes in the distal femur or proximal tibia
  • Undergoing bilateral knee surgery
  • Subject who is considered by Investigator to be an unsuitable candidate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00245271

United States, California
Kerlan-Jobe Orthopaedic Clinic
Los Angeles, California, United States, 90045
Sports, Orthopedic and Rehabilitation Medicine Associates (S.O.A.R.)
Redwood City, California, United States, 94063
United States, Colorado
Advanced Orthopedic and Sports Medicine Specialists
Denver, Colorado, United States, 80230
Colorado Orthopedic Consultants, PC
Englewood, Colorado, United States, 80110
United States, Illinois
Rush University
Chicago, Illinois, United States, 60612
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Ohio State University Sports Medicine
Columbus, Ohio, United States, 43221
United States, Pennsylvania
Temple University Orthopedics
Philadelphia, Pennsylvania, United States, 19140
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15203
Sponsors and Collaborators
Omeros Corporation
Study Director: Scott Houston Omeros Corporation

Responsible Party: Gregory Demopulos, MD, CEO, CMO, Omeros Corporation Identifier: NCT00245271     History of Changes
Other Study ID Numbers: C04516
First Posted: October 27, 2005    Key Record Dates
Last Update Posted: June 27, 2011
Last Verified: June 2011

Keywords provided by Omeros Corporation:
Musculoskeletal System
ACL reconstruction